Home・Lista de Ações・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Fechado

SetorSaúde

47.54 1.67

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

46.18

Máximo

47.62

Indicadores-chave
By Trading Economics
Rendimento	-56M -58M
Vendas	219B 219B
EPS	0.39
Margem de lucro	-0.027
Funcionários	778
EBITDA	-58B -58B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+39.44% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-57M 2.7B
Abertura anterior	45.87
Fecho anterior	47.54

Sentimento de Notícias

By Acuity

50%

168 / 340 Ranking em Healthcare

Supernus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 de ago. de 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4 de ago. de 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3 de ago. de 2026, 19:51 UTC

Social Media

News

Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31 de jul. de 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30 de jul. de 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

29 de jul. de 2026, 17:26 UTC

Supernus Pharmaceuticals Inc. shares are lower today amid volatility, with no specific news identified. The stock remains below its 20-day moving average.

28 de jul. de 2026, 17:06 UTC

Supernus Pharmaceuticals Inc. shares are higher today, recovering from an earlier decline. The stock remains near the lower end of its one-month trading range.

27 de jul. de 2026, 20:06 UTC

Supernus Pharmaceuticals Inc shares are higher Monday, despite earlier gains pulling back. Market dynamics reflect a significant decline in oil prices and inflation reassessment.

24 de jul. de 2026, 19:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, following an early peak, amid broader market dynamics influenced by a pullback in crude oil prices.

20 de jul. de 2026, 20:06 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early high amid a broader market decline during the session.

Comparação entre Pares

Variação de preço

Supernus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

39.44% parte superior

Previsão para 12 meses

Média 65.2 USD 39.44%

Máximo 67 USD

Mínimo 63 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Supernus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

168 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.